Batu Publishes Oncotarget Paper

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax

Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response

Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget.

Read the full article at businesswire.com

Continue →
0

Batu announces formation of Clinical Advisory Board

Batu Biologics Welcomes Three Visionary Leaders to Its Newly Formed Clinical Advisory Board

CAB to oversee the clinical development of Batu Biologics’ tumor vasculature targeting immunotherapeutic, ValloVax™

Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory Board to guide the company in the development of its lead program.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Recruits Dr. Vijay Mahant to SAB

Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm

Vijay Mahant, PhD, will lead efforts in the development of gene-guided precision medicine related to the ValloVax immune therapy

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board.

Read the full article at businesswire.com

Continue →
0

Batu Biologics selected to present at Cavendish Global Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Batu Biologics, an immuno-oncology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida.

Read the full article at businesswire.com

Continue →
0

Dr. Thomas Ichim joins as full-time CSO

Founder of Batu Biologics Expands Involvement as Chief Scientific Officer

Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer.

Read the full article at businesswire.com

Continue →
0

Vice Chair of Immunology at TSRI joins SAB

Vice Chairman of Immunology at The Scripps Research Institute to Assist with ValloVax™ Clinical Development

Argyrios Theofilopoulos, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Argyrios Theofilopoulos, MD of The Scripps Research Institute to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0

Batu Recruits Internationally Recognized Immunologist

Internationally-Recognized Immunologist Joins Batu Biologics’ Quest to Destroy Solid Tumors

Francesco Marincola, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax™, announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0

Batu Seeks New Approach to Inhibit Immune Checkpoints

Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells

Immune Checkpoint Silenced T Cells for More Potent, Longer Lasting Anti-Tumor Responses

Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient’s T cells.

Read the full article at businesswire.com

Continue →
0
Page 1 of 5 12345